Shares of Vaxart Inc (NASDAQ:VXRT) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy rating.

Brokerages have set a 12 month consensus target price of $4.00 for the company and are predicting that the company will post ($0.13) earnings per share for the current quarter, according to Zacks. Zacks has also given Vaxart an industry rank of 61 out of 255 based on the ratings given to its competitors.

A number of brokerages have weighed in on VXRT. Zacks Investment Research raised shares of Vaxart from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a research note on Thursday, November 21st. Brookline Capital Management began coverage on shares of Vaxart in a research note on Thursday, August 15th. They issued a “buy” rating and a $6.00 target price for the company. HC Wainwright reaffirmed a “buy” rating and issued a $2.00 target price on shares of Vaxart in a research note on Monday, November 18th. Finally, ValuEngine downgraded shares of Vaxart from a “buy” rating to a “hold” rating in a research note on Friday, November 1st.

Shares of NASDAQ VXRT remained flat at $$0.32 during trading on Tuesday. 189,671 shares of the company’s stock were exchanged, compared to its average volume of 509,432. Vaxart has a one year low of $0.25 and a one year high of $5.00. The stock has a market cap of $15.03 million, a PE ratio of -0.12 and a beta of 0.58. The company has a current ratio of 2.32, a quick ratio of 2.32 and a debt-to-equity ratio of 0.09. The business’s 50 day moving average is $0.33 and its 200 day moving average is $0.56.

Vaxart (NASDAQ:VXRT) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.04. Vaxart had a negative net margin of 222.20% and a negative return on equity of 115.71%. The company had revenue of $0.45 million during the quarter, compared to the consensus estimate of $0.44 million. As a group, equities analysts expect that Vaxart will post -0.66 EPS for the current year.

In other Vaxart news, insider Wouter Latour purchased 166,667 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The stock was acquired at an average cost of $0.30 per share, with a total value of $50,000.10. Also, major shareholder Armistice Capital Master Fund purchased 7,333,333 shares of the company’s stock in a transaction that occurred on Monday, September 30th. The shares were acquired at an average cost of $0.29 per share, with a total value of $2,126,666.57. Over the last three months, insiders have purchased 8,720,000 shares of company stock valued at $2,609,907. 7.30% of the stock is currently owned by insiders.

Several institutional investors and hedge funds have recently bought and sold shares of VXRT. Renaissance Technologies LLC raised its stake in shares of Vaxart by 120.9% during the second quarter. Renaissance Technologies LLC now owns 739,653 shares of the biotechnology company’s stock worth $496,000 after buying an additional 404,883 shares during the last quarter. Sabby Management LLC raised its stake in shares of Vaxart by 30.1% during the third quarter. Sabby Management LLC now owns 1,197,710 shares of the biotechnology company’s stock worth $430,000 after buying an additional 277,063 shares during the last quarter. Finally, Vanguard Group Inc. raised its stake in shares of Vaxart by 65.4% during the second quarter. Vanguard Group Inc. now owns 89,209 shares of the biotechnology company’s stock worth $60,000 after buying an additional 35,283 shares during the last quarter.

About Vaxart

Vaxart, Inc, a clinical-stage company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes tablet vaccines that are designed to protect against norovirus, seasonal influenza, and respiratory syncytial virus.

Featured Story: Certificate of Deposit (CD)

Get a free copy of the Zacks research report on Vaxart (VXRT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaxart Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaxart and related companies with MarketBeat.com's FREE daily email newsletter.